Related Experiment Video
Updated: Feb 4, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies
Dora Hammerl1, Dietmar Rieder2, John W M Martens3
1Laboratory of Tumor Immunology, Erasmus MC-Cancer Institute, Rotterdam, The Netherlands.
Abstract:
Adoptive transfer of TCR-engineered T cells is a potent therapy, able to induce clinical responses in different human malignancies. Nevertheless, treatment toxicities may occur and, in particular for solid tumors, responses may be variable and often not durable. To address these challenges, it is imperative to carefully select target antigens and to immunologically interrogate the corresponding tumors when designing optimal T cell therapies. Here, we review recent advances, covering both omics- and laboratory tools that can enable the selection of optimal T cell epitopes and TCRs as well as the identification of dominant immune evasive mechanisms within tumor tissues. Furthermore, we discuss how these techniques may aid in a rational design of effective combinatorial adoptive T cell therapies.
Insights
TCR-engineered T cell therapy shows promise for cancer but faces challenges. New omics and lab tools help select optimal targets and understand immune evasion for better combination therapies.
Area of Science:
- Immunotherapy
- Oncology
- Molecular Biology
Background:
- Adoptive transfer of T cell receptor (TCR)-engineered T cells is a powerful cancer treatment modality.
- Clinical responses are observed in various human malignancies, but toxicities and suboptimal durability, especially in solid tumors, remain significant hurdles.
Purpose of the Study:
- To review recent advancements in tools for selecting optimal T cell epitopes and TCRs.
- To identify dominant immune evasion mechanisms within tumor tissues.
- To guide the rational design of effective combinatorial adoptive T cell therapies.
Main Methods:
- Review of omics technologies (genomics, transcriptomics, proteomics, etc.).
- Review of laboratory-based assays and tools for immunological interrogation.
- Analysis of tumor microenvironment and immune evasion strategies.
Main Results:
- Omics and laboratory tools facilitate the selection of optimal T cell targets and TCRs.
- These methods aid in identifying key immune evasion mechanisms employed by tumors.
- The integration of these tools supports the development of more effective combination immunotherapies.
Conclusions:
- Careful antigen selection and tumor immunological interrogation are crucial for optimizing TCR-T cell therapy.
- Advanced tools enable a deeper understanding of tumor-immune interactions.
- These insights are vital for designing next-generation combinatorial adoptive T cell therapies with improved efficacy and durability.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Power
Guidelines and Strategies for Safe Computer Charting
Maintain Confidentiality and Security:
Gene Therapy
Phase-lead and Phase-lag Controllers
Instantaneous Power

